Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;8(11):890-900.
doi: 10.1016/j.trecan.2022.06.011. Epub 2022 Aug 3.

Solving the puzzle of what makes immunotherapies work

Affiliations
Review

Solving the puzzle of what makes immunotherapies work

Xiaoxiao Ma et al. Trends Cancer. 2022 Nov.

Abstract

The rapid adoption of immune checkpoint blockade (ICB) therapies has led to a need to understand the mechanistic drivers of efficacy and the identification of novel biomarkers that enrich for patients who benefit from ICB therapy. Here, we provide a perspective on emerging biomarker candidates, their underlying biological mechanisms, and how they may fit into the current landscape of ICB biomarkers. We discuss new frameworks to identify and evaluate biomarker candidates and review the opportunities and challenges of utilizing biomarker-derived models to facilitate the development of new immunotherapies.

Keywords: biomarker; immune checkpoint blockade; immunotherapy; tumor immunology.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests T.A.C. is a cofounder of Gritstone Oncology and holds equity. T.A.C. also holds equity in An2H and acknowledges grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. T.A.C. has served as an advisor for Bristol Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca, and An2H. T.A.C. is the inventor on intellectual property held by Memorial Sloan Kettering Cancer Center on using tumor mutation burden to predict immunotherapy response, with pending patent, which has been licensed to Personal Genome Diagnostics. X.M. has no interests to declare.

Figures

Figure 1.
Figure 1.. Individual investigation without broad vision leads to suboptimal understanding.
When there is insufficiently broad examination of an entity or a process, or a failure to integrate data that leads to a complete picture, flawed interpretations can result. (A) Blindfolded observers examining only single parts of an elephant can develop incomplete (and wrong) impressions of the nature of the elephant. (B) Blindfolded scientists examining the process of anti-tumor immunity may develop biomarkers that fail to capture the entirety of the process. Single biomarkers may not be sufficient for complex processes such as anti-tumor immunity. Instead, successful integration of information from diverse viewpoints can lead to a better interpretation and understanding of anti-tumor immunity. Abbreviations: DC, dendritic cell; NK, natural killer.
Figure 2.
Figure 2.. Framework for biomarker selection, model building, feedback, and improvement.
Biomarkers are analyzed in a multivariable network model to determine which ones can provide non-redundant information. Then, the candidate factors are used to build deep learning models with additional optimization of the prediction power. Factors used need to be cost effective and clinically feasible. The result can be adapted for us as nomograms or weighted scores based on the most important variables.

Similar articles

Cited by

References

    1. Haslam A. and Prasad V. (2019) Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open 2, e192535. - PMC - PubMed
    1. Yarchoan M. et al. (2017) Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 377, 2500–2501 - PMC - PubMed
    1. E.B G. (2010) Encyclopedia of Perception (Vol. 1, SAGE Publications
    1. Lee JS and Ruppin E. (2019) Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1. JAMA Oncol 5, 1614–1618 - PMC - PubMed
    1. Whitson AR and Walster HL (1912) Soils and soil fertility Webb publishing co.

Publication types

MeSH terms

Substances

LinkOut - more resources